T1	TimeFrame 228 235	14 days
T2	PrimaryOutcome 270 295	time to clinical recovery
R1	MeasuredAt Arg1:T2 Arg2:T1	
T3	PrimaryOutcome 304 354	deterioration rate after initiation of medications
T4	OutcomeDefinition 389 473	clinical symptoms (fever and respiratory symptoms) returning to normal over 48 hours
R3	DefinedAs Arg1:T2 Arg2:T4	
T5	OutcomeDefinition 516 665	presence of respiratory distress, respiratory rate ≥ 30 times/minute, oxygen saturation ≤ 93% in the resting state, and oxygenation index ≤ 300 mmHg.
R4	DefinedAs Arg1:T3 Arg2:T5	
R2	MeasuredAt Arg1:T3 Arg2:T1	
T6	SecondaryOutcome 703 722	virologic clearance
T7	TimeFrame 723 746	during the study period
T8	OutcomeDefinition 748 833	SARS‐CoV‐2‐negative conversion within 20 days, rate of SARS‐CoV‐2‐negative conversion
T9	SecondaryOutcome 836 854	clinical follow‐up
T10	OutcomeDefinition 856 1018	clinical remission rate, time to fever remission, rate of significant improvement in chest CT, percentage of patients requiring oxygen therapy, and discharge rate
T11	TimeFrame 1019 1033	within 20 days
T12	SecondaryOutcome 1044 1070	occurrence of side effects
R5	DefinedAs Arg1:T9 Arg2:T10	
R6	MeasuredAt Arg1:T9 Arg2:T11	
R7	MeasuredAt Arg1:T6 Arg2:T7	
R8	DefinedAs Arg1:T6 Arg2:T8	
T13	OutcomeDefinition 1732 1815	graded according to the Common Terminology Criteria for Adverse Events, version 5.0
R9	DefinedAs Arg1:T12 Arg2:T13	
R10	MeasuredAt Arg1:T12 Arg2:T1	
